Deciphera Pharmaceuticals Inc. (DCPH)
Symbol Info
Listed Symbol DCPH
Name Deciphera Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-2.83
Price Info
21 Day Moving Average $24.8971
21 Day EMA $26.856490
50 Day Moving Average $23.5718
50 Day EMA $24.651850
200 Day EMA $25.024520
200 Day Moving Average 24.222400
52 Week High $42.99
52 Week Low $18.55
52 Week Change $4.166700
Alpha 0.044600
Beta 1.6522
Standard Deviation 0.240675
R2 0.088066
Periods 23
Share Information
10 Day Average Volume 2,429,801
20 Day Average Volume 1,360,244
30 Day Average Volume 996,091
50 Day Average Volume 718,902
Outstanding Shares 38,215,108
Float Shares 38,118,608
Percent Float 99.75%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 195
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 2,258,326
Institute Holdings Percent 69.700000
Institute Sold Previous 3 Months 2,394,300
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months 14,983
Insider Holdings Percent 0.30%
Insider Sold Previous 3 Months 14,973
Insiders Shares Owned 96,500
Price Change
7 Day Price Change $13.5200000
7 Day Percent Change 57.58%
21 Day Price Change $15.5200000
21 Day Percent Change 72.25%
30 Day Price Change $16.0900000
30 Day Percent Change 76.95%
Month To Date Price Change $14.9000
Month To Date Percent 67.42%
90 Day Price Change $12.870001
90 Day Percent Change 53.34%
Quarter To Date $14.450001
Quarter To Date Percent 64.08%
180 Day Price Change $8.000000
180 Day Percent Change 27.59%
200 Day Price Change $11.690001
200 Day Percent Change 46.19%
Year To Date $16.010000
Year To Date Percent 76.27%
Profile
Description Deciphera Pharmaceuticals Inc is a biotechnology company, develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib.
Details
Issue Type CS
Market Cap $1,413,958,996
Sec Type
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 38,215,108
CEO Steven L. Hoerter
Employees 114
Last Audit UE
Classification
CIK 0001654151
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 500 Totten Pond Road
6th Floor
Waltham, MA 2451
Website https://www.deciphera.com
Facisimile +1 785 830-2150
Telephone +1 781 209-6400
Email cmorl@deciphera.com
Key Ratios
Profitability
EBIT Margin -502
EBITDA Margin -500.4
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $25,000,000
Revenue Per Share $0.6542
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $1,163,470,420
Price To Sales 56.558357
Price To Free Cash -11.3
PE High Last 5 Years -
Price To Book 6.2
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 6.2
Financial Strength
Total Debt To Equity 0.0
Int Coverage -1,588.6
Current Ratio 7.3
Leverage Ratio 1.1
Quick Ratio 7.1
Long Term Debt To Capital 0.01
Assets
Receivables Turnover 2.0
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -39.98
Return On Equity -45.34
Return On Capital -45.9
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NASDAQ
DCPH
Deciphera ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20190819 01:16:55